Inhibition of steryl sulfatase activity in LNCaP human prostate cancer cells

Steroids

Volumn 67, Issue 10, 2002, Pages 821-826

  Selcer, Kyle W ^a   Kabler, Heidi ^a   Sarap, Jennifer ^a   Xiao, Zili ^b   Li, Pui Kai ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer; DHEAS; LNCaP; Prostate; Sulfatase

Indexed keywords

[(4 O SULFAMOYL)TETRADECANOYL]TETRADECANOYLTYRAMINE; ANDROGEN; DANAZOL; ENZYME INHIBITOR; ESTRONE SULFATE; STERYL SULFATASE; UNCLASSIFIED DRUG; (4 O SULFAMOYL) N TRIDECANOYL TYRAMINE; (4-O-SULFAMOYL)-N-TRIDECANOYL TYRAMINE; ARYLSULFATASE; DRUG DERIVATIVE; ESTRONE; ESTRONE 3 O SULFAMATE; ESTRONE-3-O-SULFAMATE; PRASTERONE SULFATE; SULFONAMIDE; TYRAMINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVITY; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; MALE; MICROSOME; PROSTATE CANCER; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; KINETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ARYLSULFATASES; BREAST NEOPLASMS; DANAZOL; DEHYDROEPIANDROSTERONE SULFATE; ENZYME INHIBITORS; ESTRONE; FEMALE; HUMANS; KINETICS; MALE; MICROSOMES; PROSTATIC NEOPLASMS; STERYL-SULFATASE; SULFONAMIDES; TUMOR CELLS, CULTURED; TYRAMINE;

EID: 0036753565     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(02)00030-2     Document Type: Article

References (40)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin. 48:1998;6-29.
2. Kuyu H., Lee W.R., Bare R., Hall M.C., Torti F.M. Recent advances in the treatment of prostate cancer. Ann. Oncol. 10:1999;891-898.
3. Wirth M., Froehner M. A review of studies of hormonal adjuvant therapy in prostate cancer. Eur. Urol. 36(Suppl 2):1999;14-19.
4. Altwein J.E. The combination of LH-RH analogues with other treatment modalities in prostate cancer. Rec. Results Cancer Res. 153:2000;71-81.
5. Baccon-Gibod L., Laudat M.H., Guidan D., Steg A. Hormonal consequences of orchidectomy for carcinoma of the prostate with special reference to the measurement of free testosterone in saliva and prostatic dihydrotestosterone levels. Eur. Urol. 15:1988;99-102.
6. Labrie F., Dupont A., Belanger A., St-Arnaud R., Giguere M., Lacourciere Y.et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Rev. 7:1986;67-74.
7. Forti G., Salerno R., Moneti G., Zoppi S., Fiorelli G., Marinoni T.et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J. Clin. Endocrinol. Metab. 68:1989;461-468.
8. Labrie F., Dupont A., Simard J., Luu-The V., Belanger A. Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol. 24(2):1993;94-105.
9. Voigt K.D., Bartsch W. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J. Steroid Biochem. 25:1986;749-757.
10. Klein H., Bressel M., Kastendieck H., Voigt K.D. Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J. Steroid Biochem. 30:1988;119-130.
11. Bartsch W., Klein H., Schiemann U., Bauer H.W., Voigt K.D. Enzymes of androgen formation and degradation in the human prostate. Ann. NY. Acad. Sci. 595:1990;53-66.
12. Labrie F. At the cutting edge. Intracrinology. Mol. Cell Endocrinol. 78:1991;C113-C118.
13. Labrie F. Endocrine therapy of prostate cancer. Endocrinol. Metab. Clin. North Am. 20:1991;845-872.
14. Bruchovsky N., Sadar M.D., Akakura K., Goldenberg S.L., Matsuoka K., Rennie P.S. Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate. J. Steroid Biochem. Mol. Biol. 59:1996;397-404.
15. Castagnetta L.A., Carruba G., Traina A., Granata O.M., Markus M., Pavone-Macaluso M.et al. Expression of different 17β-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells. Endocrinology. 138:1997;4876-4882.
16. El-Alfy M., Luu-The V., Huang X.F., Berger L., Labrie F., Pelletier G. Localization of type 5, 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 140:1999;1481-1491.
17. Gingras S., Simard J. Induction of 3β-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon and cervix cell lines. Endocrinology. 140:1999;4573-4584.
18. Iehle C., Radvanyi F., Gil Diez de Medina S., Ouafik L.H., Gerard H., Chopin D.et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J. Steroid Biochem. Mol. Biol. 68:1999;189-195.
19. Harper M.E., Pike A., Peeling W.B., Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue in vivo and in vitro. J. Endocrinol. 60:1974;117-125.
20. Labrie C., Belanger A., Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 123:1988;1412-1417.
21. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med. 321:1989;419-424.
22. Denis L. Role of maximal androgen blockade in advanced prostate cancer. Prostate. 5(Suppl):1994;17-22.
23. Miller WL, Tyrrell JB. The adrenal cortex. In: Felig P, Baxter JD, Frohman LA, editors. Endocrinology and metabolism, 3rd ed. New York: McGraw-Hill, 1995. p. 555-11.
24. Reed M.J., Purohit A., Howarth N.M., Potter B.V.L. Steroid sulphatase inhibitors: a new endocrine therapy. Drugs Future. 19:1994;673-680.
25. Selcer K.W., Hegde P., Li P.K. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyltyramines. Cancer Res. 57:1997;702-707.
26. Purohit A., Woo L.W.L., Singh A., Winterborn C.J., Potter B.V.L., Reed M.J. In vivo activity of 4-methylcoumarin-7-O-sulfamate a nonsteroidal nonestrogenic steroid sulfatase inhibitor. Cancer Res. 56:1996;4950-4955.
27. Negri-Cesi P., Motta M. Androgen metabolism in the human prostatic cell line LNCaP. J. Steroid Biochem. Mol. Biol. 51:1994;89-96.
28. Li P.K., Chu G.H., Guo J.P., Peters A., Selcer K.W. Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids. 63:1998;425-432.
29. Kolli A., Chu G.H., Rhodes M.E., Inoue K., Selcer K.W., Li P.K. Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 68:1999;31-40.
30. Howarth N.M., Purohit A., Reed M.J., Potter B.V.L. Estrone sulphamates: potent inhibitors of estrone sulphatase with therapeutic potential. J. Med. Chem. 37:1994;219-221.
31. Li P.K., Milano S., Kluth L., Rhodes M.E. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 59:1996;41-48.
32. Farnsworth W.E. Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids. 21:1973;647-664.
33. Cowan R.A., Cowan S.K., Grant J.K., Elder H.Y. Biochemical investigations of separated epithelium and stroma from benign hyperplastic prostatic tissue. J. Endocrinol. 74:1977;111-120.
34. Klein H., Molwitz T., Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: characterization and quantification of the enzyme in epithelium and stroma. J. Steroid Biochem. 33:1989;195-200.
35. Selcer K.W., Jagannathan S., Li P.K. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J. Steroid Biochem. Mol. Biol. 59:1996;83-91.
36. Purohit A., Dauvois S., Parker M.G., Potter B.V.L., Williams G.J., Reed M.J. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J. Steroid Biochem. Mol. Biol. 50:1994;101-104.
37. Dao T.L., Libby P.R. Conjugation of steroid hormones by normal and neoplastic tissues. J. Clin. Endocrinol. Metab. 28:1968;1431-1439.
38. Carlstrom K., Doberl A., Pousette A., Rannevik G., Wilking N. Inhibition of steroid sulfatase activity by Danazol. Acta. Obstet. Gynaec. Scand. Suppl 123:1984;107-111.
39. Evans T.R., Rowlands M.G., Jarman M., Coombes R.C. Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J. Steroid Biochem. Mol. Biol. 39:1991;493-499.
40. Purohit A., Williams G.J., Howarth N.M., Potter B.V.L., Reed M.J. Inactivation of steroid sulfatase by an active site-directed inhibitor estrone-3-O-sulfamate. Biochemistry. 34:1995;11508-11514.